Halogenated composition, method for preparing same and uses thereof

Abstract

The invention concerns pharmaceutical composition including (i) at least a halogenated compound and (ii) at least N-halogenated derivative of at least a compound selected from zwitterionic compounds and/or amino acids. The halogenated compound is advantageously an alkaline metal hypochlorite, and preferably sodium hypochlorite, and N-halogenated derivative is preferably an N-halogenated taurine derivative and particularly a taurine N-haloamine derivative and even more preferably taurine N-chloramine. The invention also concerns the preparation of the compositions and their uses as very large spectrum antiseptic, anti-inflammatory agent and as immunity modulator, without stimulating myeloperoxidase activity.

It is claimed:  
     
         1 ) A pharmaceutical composition comprising: 
 (i) at least one halogenated compound, and    (ii) at least one N-halogenated derivative of at least one compound selected from zwitterionic and/or amino acid compounds, 
 wherein the composition does not generate substantial stimulation of myeloperoxidase activity in a mammal.  
   
     
     
         2 ) A pharmaceutical composition according to  claim 1 , wherein halogens of (i) the halogenated compound and (ii) the N-halogenated derivative, which may be the same or different, are selected from the group consisting of fluorine, iodine, bromine and chlorine.  
     
     
         3 ) A pharmaceutical composition according to  claim 1 , wherein (i) the halogenated compound is a hypochlorite of an alkaline metal.  
     
     
         4 ) A pharmaceutical composition according to  claim 3 , wherein the hypochlorite is sodium hypochlorite.  
     
     
         5 ) A pharmaceutical composition according to  claim 1 , wherein (ii) the N-halogenated derivative is an N-halogen derivative of taurine.  
     
     
         6 ) A pharmaceutical composition according to  claim 5 , wherein the taurine is taurine N-haloamine.  
     
     
         7 ) A pharmaceutical composition according to  claim 5 , wherein the taurine is taurine N-chloramine.  
     
     
         8 ) A pharmaceutical composition according to  claim 4 , wherein the sodium hypochlorite concentration is between about 1 mole/liter and about 1 picomole/liter of available chlorine.  
     
     
         9 ) A pharmaceutical composition according to  claim 7 , wherein the concentration of the taurine N-chloramine is between about 5 moles/liter and about 0.01 femtomoles/liter.  
     
     
         10 ) A pharmaceutical composition according to  claim 1 , wherein both (i) the halogenated compound and (ii) the N-halogenated derivative are mixed in with a pharmaceutically acceptable excipient.  
     
     
         11 ) A pharmaceutical composition according to  claim 1 , further comprising a pharmaceutically compatible agent which modifies at least one physicochemical property of the composition selected from the group consisting of stability, pH, pKa, density, solubility, viscosity, coloring, water/ectanol sharing factor, and surface-active, oxidative, olfactory, or gustatory properties.  
     
     
         12 ) A method of preparing a pharmaceutical composition comprising mixing: 
 (i) at least one halogenated compound,    (ii) at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives, and    (iii) optionally at least one pharmaceutically acceptable excipient.    
     
     
         13 ) A method of preparing a pharmaceutical composition comprising mixing: 
 at least one halogenated compound, and    at least one zwitterionic compound and/or at least one amino acid or their derivatives, and    optionally at least one excipient to obtain at least one N-halogenated derivative, and at least one halogenated compound in a sufficient therapeutic amount to not substantially stimulate myeloperoxidase activity in a mammal.    
     
     
         14 ) A method according to  claim 13 , wherein the zwitterionic compound and/or the amino acid is taurine or a taurine analog.  
     
     
         15 ) A method according to  claim 13 , wherein: 
 the halogenated compound is a hypochlorite of alkaline metal, and    the N-halogenated derivative is N-chlorinated.    
     
     
         16 ) A method according to  claim 15 , wherein the hypochlorite is sodium hypochorite.  
     
     
         17 ) A method according to  claim 15 , wherein the N-halogenated derivative is N-chlorinated.  
     
     
         18 ) A method according to  claim 16 , wherein the concentration of the sodium hypochlorite is between about 6 moles/liter and about 1000.01 femtomoles/liter.  
     
     
         19 ) A method according to  claim 14 , wherein the concentration of the taurine is between about 5 moles/liter and about 0.01 femtomoles/liter.  
     
     
         20 ) A method for treatment and/or preventing viral infections, and/or bacterial infections, and/or parasitical infections, and/or fungal infections, and/or diseases generated from non conventional transmissible agents, in humans or animals comprising administring to a human or animal a pharmaceutically effective amount of a pharmaceutical composition comprising: 
 at least one halogenated compound, and    at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or the amino acids or their derivatives, without substantial stimulation of myeloperoxidase activity in the human or animal.    
     
     
         21 ) A method of treating chronic inflammation, and/or progressive inflammation, and/or acute inflammation in humans or animals comprising administering to a human or animal a pharmaceutically effective amount of a pharmaceutical composition comprising: 
 at least one halogenated compound, and    at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives, without substantial stimulation of myeloperoxidase activity in the human or animal.    
     
     
         22 ) A method of modulating immunity, in humans or animals comprising administering to a human or animal a pharmaceutically effective amount of a pharmaceutical composition comprising: 
 at least one halogenated compound, and    at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives, without substantial stimulatation of myeloperoxidase activity in the human or animal.    
     
     
         23 ) A method of stimulating tissue healing in humans or animals comprising administering to a human or animal a pharmaceutically effective amount of a pharmaceutical composition comprising: 
 at least one halogenated compound, and    at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives, without substantial stimulation of myeloperoxidase activity in the human or animal.    
     
     
         24 ) A method of pre-surgically, and/or per-surgically, and/or post-surgically irrigating in humans or animals comprising contacting the surgical site with a composition comprising: 
 at least one halogenated compound, and    at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives, without substantial stimulation of myeloperoxidase activity in the human or animal.    
     
     
         25 ) A method according to  claim 20 , wherein the composition treats lesions and infections linked to periodontitis.  
     
     
         26 ) A method according to  claim 20 , wherein the composition treats lesions and infections linked to herpesviridiae.